rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SCNI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands
      Nov 5Yahoo FinanceSCNI
      Scinai secures CDMO deal, raises $5.3M in financing
      Oct 20Investing.comSCNI
      Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing

      --Scinai Immunotherapeutics Ltd. today issued the following letter to shareholders from Chief Executive Officer Amir Reichman. Our new agreement with a U.S.- based, Nasdaq-listed biopharmaceutical company includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms. As of October 20, 2026, our Committed...

      Oct 20NasdaqSCNI
      Scinai closes $4M financing through private placement
      Oct 16Investing.comSCNI
      Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement
      Oct 16MorningstarSCNI
      Scinai raises $4M through private placement and warrant deal
      Oct 14Investing.comSCNI
      Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement
      Oct 14MorningstarSCNI
      Why Is Scinai Immunotherapeutics Stock Gaining Tuesday? - Scinai Immunotherapeutics (NASDAQ:SCNI)

      Scinai Immunotherapeutics stock jumped 27% after securing a $5.1M biopharma manufacturing deal. Details on SCNI's major contract win.

      Oct 13BenzingaSCNI
      Scinai Expands CDMO Business with $5.1 Million Manufacturing Agreement as Committed Orders Rise 300%
      Oct 13Yahoo FinanceSCNI
      12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Alaunos Therapeutics (NASDAQ:TCRT), Scinai

      Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose

      Oct 13BenzingaSCNITCRT
      Scinai secures $5.1M manufacturing deal with U.S. biopharma firm
      Oct 13Investing.comSCNI
      Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

      --Scinai Immunotherapeutics Ltd., a biopharmaceutical company operating a growing contract development and manufacturing organization alongside an immunology-focused therapeutic development platform, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has entered into a definitive development and clinical...

      Oct 13NasdaqSCNI
      Scinai regains compliance with Nasdaq minimum bid price rule
      Sep 21Investing.comSCNI
      Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
      Sep 21Yahoo FinanceSCNI
      12 Health Care Stocks Moving In Monday's Intraday Session
      Sep 14BenzingaEUDASCNI
      Nasdaq Down Over 200 Points; Cellectis Shares Plunge
      Sep 14BenzingaCLLSSCNI
      12 Health Care Stocks Moving In Monday's Pre-Market Session
      Sep 14BenzingaSCNI
      12 Health Care Stocks Moving In Friday's After-Market Session
      Sep 11BenzingaCRBPSCNI
      Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business

      Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today announced a strategic refocusing of its R&D portfolio following the conclusion of its option and license arrangements with PinCell S.r.l. relating to PC111.

      Sep 8Yahoo FinanceSCNI
      Earnings call transcript: Scinai posts H1 2026 revenue growth as losses persist
      Aug 26Investing.comSCNI
      Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

      Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

      Aug 24Yahoo FinanceSCNI
      Scinai reports H1 2026 results, announces U.S. customer expansion
      Aug 24Investing.comSCNI

      This is the newest page. Registered accounts read further back.